Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06384911 · ClinicalTrials.gov registry record · NA

InvesT1D: Promoting Adolescent Investment in Diabetes Care

A NA study of Type 1 Diabetes, sponsored by Harvard Pilgrim Health Care.

Recruiting
Registry status
NA
Development phase
96
Enrollment target
1
Study location

NCT06384911 is a NA study of Type 1 Diabetes that is actively recruiting participants, run by Harvard Pilgrim Health Care. The registered enrollment target is 96 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06384911, a NA study of Type 1 Diabetes, is actively recruiting participants, sponsored by Harvard Pilgrim Health Care.

RECRUITING
Registry status
NA
Development phase
96 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes. Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management and clinical outcomes goals during the study. Researchers will compare changes in glucose levels, as well as adolescent and caregiver person-reported outcomes between groups.

Conditions Studied

Interventions

  • BEHAVIORAL Financial Incentives Program

Study Locations (1)

Washington

  • Seattle Children's - Seattle

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2024-06-25
Est. Completion 2027-10-31
Phase NA

Sponsor

Harvard Pilgrim Health Care

28 total trials

What the Registry Record Tells You About NCT06384911

The ClinicalTrials.gov registry entry for NCT06384911 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (88% lower). The listed sponsor is Harvard Pilgrim Health Care, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Financial Incentives Program is the first listed.

NCT06384911 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT06384911 about?

NCT06384911 is a clinical study titled "InvesT1D: Promoting Adolescent Investment in Diabetes Care". The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes. Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management an...

What is the current status of trial NCT06384911?

This trial is currently recruiting. It is a NA study. The enrollment target is 96 participants. The study started on 2024-06-25. Estimated completion is 2027-10-31.

What conditions does trial NCT06384911 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT06384911?

The interventions under investigation include: Financial Incentives Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06384911?

This trial is sponsored by Harvard Pilgrim Health Care, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06384911 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.